Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pharma-Bio Serv (PBSV) EBITDA (2016 - 2026)

Pharma-Bio Serv (PBSV) has disclosed EBITDA for 15 consecutive years, with -$133272.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA rose 13.53% year-over-year to -$133272.0, compared with a TTM value of -$637662.0 through Oct 2025, up 50.48%, and an annual FY2025 reading of -$637662.0, up 50.48% over the prior year.
  • EBITDA was -$133272.0 for Q4 2025 at Pharma-Bio Serv, up from -$313877.0 in the prior quarter.
  • Across five years, EBITDA topped out at $460466.0 in Q3 2023 and bottomed at -$4.8 million in Q4 2021.
  • Average EBITDA over 5 years is -$174329.4, with a median of $58598.5 recorded in 2022.
  • The sharpest move saw EBITDA tumbled 3262.58% in 2021, then soared 103.52% in 2022.
  • Year by year, EBITDA stood at -$4.8 million in 2021, then skyrocketed by 103.52% to $168962.0 in 2022, then plummeted by 130.64% to -$51765.0 in 2023, then tumbled by 197.75% to -$154130.0 in 2024, then grew by 13.53% to -$133272.0 in 2025.
  • Business Quant data shows EBITDA for PBSV at -$133272.0 in Q4 2025, -$313877.0 in Q3 2025, and -$98322.0 in Q2 2025.